9 June 2016 - The EMA has published an EPAR for Samsung Bioepis' Flixabi (infliximab).

The European Commission approved Flixabi on 26 May 2016 for certain patients with:

• Rheumatoid arthritis
• Crohn's disease
• Ulcerative colitis
• Ankylosing spondylitis
• Psoriatic arthritis
• Psoriasis

Flixabi will be subjected to additional monitoring by the EMA.

For more details, go to: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004020/human_med_001980.jsp&mid=WC0b01ac058001d124